Stuart A. Grossman

Oncology

201 North Broadway Street, Viragh BLDG 5th FL
Viragh BLDG 5th FL
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 147 publications

SEQUENTIAL, NON-INVASIVE, NEUROSENSORY MONITORING DURING CHEMOTHERAPY: CLINICAL CONSEQUENCES OF IDENTFYING NEUROPATHY.

SEQUENTIAL, NON-INVASIVE, NEUROSENSORY MONITORING DURING CHEMOTHERAPY: CLINICAL CONSEQUENCES OF IDENTFYING NEUROPATHY.

Journal: Journal of reconstructive microsurgery

Published: June 11, 2026

Sequential, Noninvasive, Neurosensory Monitoring During Chemotherapy: Clinical Consequences of Identifying Neuropathy.

Sequential, Noninvasive, Neurosensory Monitoring During Chemotherapy: Clinical Consequences of Identifying Neuropathy.

Journal: Journal of reconstructive microsurgery

Published: June 11, 2026

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

Journal: AJNR. American journal of neuroradiology

Published: February 19, 2026

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Journal: Neuro-oncology

Published: November 26, 2025

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Journal: Neuro-oncology

Published: November 26, 2025

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Journal: Nature medicine

Published: August 29, 2025

Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.

Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.

Journal: Neuro-oncology advances

Published: July 24, 2025

Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.

Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.

Journal: Neuro-oncology

Published: July 14, 2025

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.

Journal: Neuro-oncology

Published: July 14, 2025

Volumetric Analysis of Contrast Enhancement in Patients With Newly Diagnosed Glioblastomas.

Volumetric Analysis of Contrast Enhancement in Patients With Newly Diagnosed Glioblastomas.

Journal: Neurosurgery

Published: May 20, 2025

Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas.

Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas.

Journal: Neuro-oncology advances

Published: April 14, 2025

A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.

A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.

Journal: Neuro-oncology

Published: March 22, 2025

Showing 1-12 of 147

Last Updated: 09/26/2026